コンテンツへスキップ
Merck

HMYOMAG-56K

MILLIPLEX® Human Myokine Panel

Configurable Human Myokine 15-Plex Panel

ログインで組織・契約価格をご覧ください。

この商品について

UNSPSC Code:
12161503
NACRES:
NA.84
eCl@ss:
32161000


製品名

MILLIPLEX® Human Myokine Panel,

description

Configurable Human Myokine 15-Plex Panel

Quality Level

species reactivity

human

packaging

pkg of 1 ea

manufacturer/tradename

Milliplex®

technique(s)

multiplexing: suitable

input

serum
plasma
cell culture supernatant(s)

assay range

accuracy: 100%
(Apelin), accuracy: 92%
(IL-15), accuracy: 96%
(FSTL-1), accuracy: 97%
(LIF), accuracy: 98%
(Oncostatin M (OSM)), sensitivity: 0.9 pg/mL
(MinDC+2SD; IL-6), sensitivity: 14 pg/mL
(MinDC+2SD; FGF-21), sensitivity: 259 pg/mL
(MinDC+2SD; Myostatin/GDF8), sensitivity: 281 pg/mL
(MinDC+2SD; Irisin), sensitivity: 4 pg/mL
(MinDC+2SD; LIF), sensitivity: 40 pg/mL
(MinDC+2SD; Fractalkine/CX3CL1), sensitivity: 5 pg/mL
(MinDC+2SD; IL-15), sensitivity: 59 pg/mL
(MinDC+2SD; Osteocrin/Musclin), sensitivity: 6 pg/mL
(MinDC+2SD; Oncostatin M (OSM)), sensitivity: 64 pg/mL
(MinDC+2SD; Apelin), sensitivity: 7.5 ng/mL
(MinDC+2SD; Osteonectin (SPARC)), sensitivity: 737 pg/mL
(MinDC+2SD; Follistatin-like Protein 1 (FSTL1)), sensitivity: 815 pg/mL
(MinDC+2SD; Erythropoietin (EPO)), sensitivity: 9 pg/mL
(MinDC+2SD; BDNF), sensitivity: 9.8 pg/mL
(MinDC+2SD; FABP3), standard curve range: 0.6-2,400 pg/mL
(IL-6), standard curve range: 10-40,000 pg/mL
(LIF), standard curve range: 122-500,000 pg/mL
(Apelin), standard curve range: 2-10,000 pg/mL
(BDNF), standard curve range: 2-10,000 pg/mL
(IL-15), standard curve range: 2-6,000 pg/mL
(Oncostatin M (OSM)), standard curve range: 24-100,000 pg/mL
(FABP3), standard curve range: 244-1,000,000 pg/mL
(Erythropoietin (EPO)), standard curve range: 244-1,000,000 pg/mL
(Irisin), standard curve range: 488-2,000,000 pg/mL
(Follistatin-like Protein 1 (FSTL1)), standard curve range: 488-2,000,000 pg/mL
(Myostatin/GDF8), standard curve range: 49-200,000 pg/mL
(Fractalkine/CX3CL1), standard curve range: 49-200,000 pg/mL
(Osteocrin/Musclin), standard curve range: 5-20,000 pg/mL
(FGF-21), standard curve range: 7-30,000 ng/mL
(Osteonectin (SPARC)), inter-assay cv: <15%
intra-assay cv: <10%
(Apelin), inter-assay cv: <15%
intra-assay cv: <10%
(BDNF), inter-assay cv: <15%
intra-assay cv: <10%
(Erythropoietin (EPO)), inter-assay cv: <15%
intra-assay cv: <10%
(FABP3), inter-assay cv: <15%
intra-assay cv: <10%
(FGF-21), inter-assay cv: <15%
intra-assay cv: <10%
(Follistatin-like Protein 1 (FSTL1)), inter-assay cv: <15%
intra-assay cv: <10%
(Fractalkine/CX3CL1), inter-assay cv: <15%
intra-assay cv: <10%
(IL-15), inter-assay cv: <15%
intra-assay cv: <10%
(IL-6), inter-assay cv: <15%
intra-assay cv: <10%
(Irisin), inter-assay cv: <15%
intra-assay cv: <10%
(LIF), inter-assay cv: <15%
intra-assay cv: <10%
(Myostatin/GDF8), inter-assay cv: <15%
intra-assay cv: <10%
(Oncostatin M (OSM)), inter-assay cv: <15%
intra-assay cv: <10%
(Osteocrin/Musclin), inter-assay cv: <20%
intra-assay cv: <10%
(Osteonectin (SPARC))

detection method

fluorometric (Luminex® xMAP® technology)

shipped in

wet ice

storage temp.

2-8°C

General description

FABP3, Myosin Light Chain 3 (MYL3), Cardiac Troponin I (cTnI), Cardiac Troponin T (cTnT), and Creatine Kinase Muscle (CKM) are key biomarkers of cardiac muscle injury and stress. These analytes help detect myocardial damage, assess cardiac function, and monitor cardiotoxicity, making them valuable in cardiovascular research and drug safety studies. Their combined measurement supports sensitive and specific evaluation of cardiac health in human samples.

Application

MILLIPLEX® Qualified assays undergo rigorous assay development, verification, and Quality Control testing to achieve optimal performance Simultaneously analyze up to 15 analytes in human serum, plasma, or cell/tissue culture supernatant samples.

Analytes included: BDNF, Decorin, FSTL1, IL-6, IL-15, Irisin, LIF, MCP-1/CCL2, Myostatin, Osteocrin, Osteonectin, SPARC, TGF-β1, VEGF-A, and VEGF-D

Assay Characteristics: Refer to kit protocol for assay cross-reactivity, sensitivity, precision, and accuracy.

Features and Benefits

Features:

  • Simultaneous quantification of 15 myokines and related biomarkers
  • Based on Luminex® xMAP® magnetic bead technology for high-throughput multiplexing
  • Compatible with serum, plasma, and cell/tissue culture supernatants or lysates
  • Wide dynamic range and high sensitivity for low-abundance targets
  • Includes all necessary reagents and standards for streamlined workflow
  • Rigorously tested for cross-reactivity, precision, and reproducibility
Benefits:

  • Enables comprehensive profiling of muscle-secreted cytokines and growth factors
  • Reduces sample volume requirements while maximizing data output
  • Saves time and cost compared to running multiple single-plex assays
  • Supports research in muscle metabolism, inflammation, and regenerative biology
  • Provides reliable, reproducible data for both basic and translational research

Legal Information

Luminex is a registered trademark of Luminex Corporation
MILLIPLEX is a registered trademark of Merck KGaA, Darmstadt, Germany
xMAP is a registered trademark of Luminex Corp

Disclaimer

For research use only. Not for use in diagnostic procedures.

Label License/Sticker for Assay Product:

By opening the packaging containing this Assay Product (which contains fluorescently labeled microsphere beads authorized by Luminex Corporation) or using this Assay Product in any manner, you are consenting and agreeing to be bound by the End User Terms and Conditions and the End User License Agreement available at http://support.diasorin.com/end-user-terms-and-conditions/. If you do not agree to all of the terms and conditions, you must promptly return this Assay Product for a full refund prior to using it in any manner.


signalword

Danger

Hazard Classifications

Acute Tox. 3 Dermal - Acute Tox. 4 Inhalation - Acute Tox. 4 Oral - Aquatic Chronic 2 - Eye Dam. 1 - Skin Irrit. 2 - Skin Sens. 1 - STOT RE 2

target_organs

Respiratory Tract

保管分類

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

wgk

WGK 3


適用法令

試験研究用途を考慮した関連法令を主に挙げております。化学物質以外については、一部の情報のみ提供しています。 製品を安全かつ合法的に使用することは、使用者の義務です。最新情報により修正される場合があります。WEBの反映には時間を要することがあるため、適宜SDSをご参照ください。

Please refer to KIT Component information

pdsc

Please refer to KIT Component information

prtr

Please refer to KIT Component information

fsl

Please refer to KIT Component information

ishl_indicated

Please refer to KIT Component information

ishl_notified

Please refer to KIT Component information

cart

キットコンポーネントの情報を参照してください

jan



試験成績書(COA)

製品のロット番号・バッチ番号を入力して、試験成績書(COA) を検索できます。ロット番号・バッチ番号は、製品ラベルに「Lot」または「Batch」に続いて記載されています。

以前この製品を購入いただいたことがある場合

文書ライブラリで、最近購入した製品の文書を検索できます。

文書ライブラリにアクセスする


関連コンテンツ

MILLIPLEX®マルチプレックス代謝アッセイなどのマルチプレックス・イムノアッセイは、メタボリックシンドローム研究に重要です。糖尿病や肥満など、関連するさまざまな病態の全体像を把握でき、時間とサンプル量を節約できるためです。

MILLIPLEX® Human Myokine Panelのようなマルチプレックスマイオカインイムノアッセイにより、研究者は複数の筋分泌因子を同時に測定することができ、関連する疾患についてより多くの知見を得ることができます。

Simplify protein biomarker discovery with the MILLIPLEX® PLEXpedition 115-Plex Multiplex Screening Panel. Effortlessly screen cytokines and other markers with Luminex® technology.

すべての関連コンテンツを見る

Kelly Ann Hutchinson et al.
Frontiers in physiology, 10, 1188-1188 (2019-10-28)
It is recommended that women accumulate 150-min of weekly moderate-intensity physical activity (MPA) when pregnant. Engaging in regular physical activity (PA) confers many health benefits to both the mother and the fetus. However, the molecular mechanisms by which these health
Javier Diaz-Castro et al.
Frontiers in nutrition, 8, 761213-761213 (2021-11-09)
Practicing exercise is one of the best strategies to promote well-being and quality of life, however physical activity in schoolchildren and adolescents is developed in an unpredictable, intermittent way and in short periods. There are relatively few intervention studies investigating